@EricTopol In a LinkedIn post, I provide some additional mechanistic explanation for the absence of CV benefit with pelacarsen in patients with advanced atherosclerosis: lnkd.in/p/eF_r5xZK
Today #AHA26 and @NEJM the 2 big trials of secondary prevention of heart disease with an IL-6 antibody and Lp(a) antisense oligonucleotide. No beneficial effect, overall and across all subgroupsView quoted post on X
nejm.org/doi/full/10.10…
nejm.org/doi/full/10.10…